Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

CAGAYAN DE ORO CITY (PIA) — The Philippine Health Insurance Corporation (PhilHealth) reaffirmed its commitment to supporting ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...

Lynae Darbes, PhD, presented research on the effectiveness of a home-based intervention for HIV prevention among couples ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

A group of leading African researchers trying to develop effective vaccines against HIV is trying to figure out how to ...

The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...

A groundbreaking annual injection designed to protect against Human Immunodeficiency Virus (HIV) has successfully ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

An annual jab to protect against HIV “shows potential”, according to an early study. Millions of people around the world are ...